Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.31 |
| ▸ | CPB1 | P15086 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12305758 | 0.84 | EGLN1 (0.39) | EGLN1TSHRKDM4ELDHASRR | |
| SCHEMBL2926536 | 0.81 | TSHR (0.60) | EGLN1TSHRKDM4ELDHASRR | |
| SCHEMBL2926538 | 0.81 | TSHR (0.60) | EGLN1TSHRKDM4ELDHASRR | |
| SCHEMBL12101265 | 0.81 | EGLN1 (0.40) | EGLN1TSHRKDM4ELDHASRR | |
| SCHEMBL15741484 | 0.81 | TSHR (0.60) | EGLN1TSHRKDM4ELDHASRR | |
| SCHEMBL5607058 | 0.80 | MGAM (0.46) | EGLN1TSHRKDM4ERECQLALDH1A1 | |
| SCHEMBL1597248 | 0.79 | ALDH1A1 (0.50) | EGLN1TSHRKDM4EALDH1A1CYP2D6 | |
| SCHEMBL28083775 | 0.78 | ALDH1A1 (0.33) | EGLN1TSHRALDH1A1TET2HCAR2 | |
| SCHEMBL14286300 | 0.78 | TET2 (0.37) | EGLN1TSHRTGFBR1ALDH1A1TET2 | |
| SCHEMBL7046252 | 0.78 | GRIK1 (0.39) | EGLN1TSHRKDM4ELDHASRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201815-A1 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | XDH, PON1, CBR1 | EGLN1 965/4885TSHR 3138/4885KDM4E 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.